CTEC Global X CleanTech ETF

HAYWARD, Calif., April 30 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC) today announced that it will release its fiscal 2007 fourth quarter and year-end financial results prior to the market's opening on Wednesday, May 9, 2007. The Company will also host a conference call and webcast available to all interested parties at 7:00 a.m. PT. The dial-in number to access the call is (800) 896-8445 or, from international locations, +1 (785) 830-1916. Alternatively, you may go to the Cholestech website, http://www.cholestech.com/ for the link to the webcast. Cholestech's fiscal 2007 fourth quarter and year-end financial results may be accessed by: News Release: Visit the Cholestech website or call Financial Dynamics at (415) 439-4500 to have a copy of the news release faxed or emailed. Conference Call: Dial (800) 896-8445 or, from international locations, +1 (785) 830-1916 prior to the start of the call at 7:00 a.m. PT. The call will also be webcast live at http://www.cholestech.com/. Please visit the site prior to the broadcast to ensure your connection. Replay: The conference call replay will be available by telephone through Wednesday, May 23rd until 9:00 p.m. PT. To access the conference call replay, dial (800) 283-8217 or from international locations, +1 (402) 220-0868. There is no pass code required. A web archive of the call will also be made available at Cholestech's website. For additional information on Cholestech, visit the Company's website http://www.cholestech.com/. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver enzymes at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM)* Systems and the hs-CRP test, which is cleared by the FDA for use in moderate complexity labs, to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. *The GDX system is 510(k) cleared for prescription home use and, accordingly, is CLIA waived. NOTE: Cholestech LDX is a registered trademark and Cholestech GDX is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at http://www.cholestech.com/. CTEC-F DATASOURCE: Cholestech Corporation CONTACT: Jack Glenn, Chief Financial Officer of Cholestech Corporation, +1-510-781-5065, or ; or investors, Brendan Lahiff of Financial Dynamics, +1-415-439-4504, or , for Cholestech Corporation Web site: http://www.cholestech.com/

Copyright